Rbm10 deficiency suppresses NF-κB-mediated responses in vivo in mouse models and in vitro [30], which supports role for the de novo SVs in increasing SLE risk as NF-κB-activity in T-cells from SLE patients has been shown to be greatly decreased [31]. The gene discussed is RBM10; the disease is systemic lupus erythematosus.